Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Extension Program of Iptacopan in Primary IgA Nephropathy
NCT04557462Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Sep 2021; status: recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04557462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557462.